StockData
Ultragenyx Pharmaceutical Inc. logo

Ultragenyx Pharmaceutical Inc. (RARE) stock

RARENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30
$16.70+0.80 (+5.03%)

Close on Nov 17, 2026Market cap $1.65BP/E –Yield –

Ultragenyx Pharmaceutical ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Ultragenyx Pharmaceutical's ebitda for the twelve months ending Jun 30, 2026 was -$495.17M. For fiscal 2025 it was -$500.00M. The highest annual figure on record is -$15.67M in fiscal 2012.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$500.00M–
FY2024Dec 31, 2024-$500.00M–
FY2023Dec 31, 2023-$543.00M–
FY2022Dec 31, 2022-$630.70M–
FY2021Dec 31, 2021-$368.50M–
FY2020Dec 31, 2020-$317.86M–
FY2019Dec 31, 2019-$415.63M–
FY2018Dec 31, 2018-$351.84M–
FY2017Dec 31, 2017-$323.12M–
FY2016Dec 31, 2016-$244.58M–
FY2015Dec 31, 2015-$146.35M–
FY2014Dec 31, 2014-$56.09M–
FY2013Dec 31, 2013-$31.84M–
FY2012Dec 31, 2012-$15.67M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$67.00M–
Q1 FY2026Mar 31, 2026-$161.00M–
Q4 FY2025Dec 31, 2025-$104.50M–
Q3 FY2025Sep 30, 2025-$162.68M–
Q2 FY2025Jun 30, 2025-$99.00M–
Q1 FY2025Mar 31, 2025-$134.00M–
Q4 FY2024Dec 31, 2024-$112.77M–
Q3 FY2024Sep 30, 2024-$123.23M–
Q2 FY2024Jun 30, 2024-$107.50M–
Q1 FY2024Mar 31, 2024-$156.50M–
Q4 FY2023Dec 31, 2023-$113.63M–
Q3 FY2023Sep 30, 2023-$137.91M–
Q2 FY2023Jun 30, 2023-$142.60M–
Q1 FY2023Mar 31, 2023-$148.87M–
Q4 FY2022Dec 31, 2022-$140.67M–
Q3 FY2022Sep 30, 2022-$220.37M–
Q2 FY2022Jun 30, 2022-$137.11M–
Q1 FY2022Mar 31, 2022-$132.54M–
Q4 FY2021Dec 31, 2021-$99.03M–
Q3 FY2021Sep 30, 2021-$86.61M–
Q2 FY2021Jun 30, 2021-$79.66M–
Q1 FY2021Mar 31, 2021-$103.20M–
Q4 FY2020Dec 31, 2020-$92.95M–
Q3 FY2020Sep 30, 2020-$47.22M–
Q2 FY2020Jun 30, 2020-$59.87M–
Q1 FY2020Mar 31, 2020-$117.81M–
Q4 FY2019Dec 31, 2019-$92.28M–
Q3 FY2019Sep 30, 2019-$115.89M–
Q2 FY2019Jun 30, 2019-$110.37M–
Q1 FY2019Mar 31, 2019-$97.10M–
Q4 FY2018Dec 31, 2018-$87.40M–
Q3 FY2018Sep 30, 2018-$85.29M–
Q2 FY2018Jun 30, 2018-$88.82M–
Q1 FY2018Mar 31, 2018-$90.33M–
Q4 FY2017Dec 31, 2017-$94.32M–
Q3 FY2017Sep 30, 2017-$82.62M–
Q2 FY2017Jun 30, 2017-$77.39M–
Q1 FY2017Mar 31, 2017-$68.79M–
Q4 FY2016Dec 31, 2016-$69.39M–
Q3 FY2016Sep 30, 2016-$64.75M–

More Ultragenyx Pharmaceutical figures

See a number that looks wrong?